Tracking the NRIX option chain helps you see every strike and expiry on Nurix Therapeutics Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Nurix Therapeutics Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of NRIX options activity at a glance. Use our scanner to monitor the NRIX option chain in real time and filter for the NRIX options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For NRIX stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the NRIX option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where NRIX stock options are being actively traded and where they are not.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Nurix Therapeutics Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen NRIX options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of NRIX stock options — let the full option chain come to you, pre-filtered and ready to trade.
